149 related articles for article (PubMed ID: 35262847)
1. Pooled Population Pharmacokinetic Analysis for Exploring Ciprofloxacin Pharmacokinetic Variability in Intensive Care Patients.
Guo T; Abdulla A; Koch BCP; van Hasselt JGC; Endeman H; Schouten JA; Elbers PWG; Brüggemann RJM; van Hest RM;
Clin Pharmacokinet; 2022 Jun; 61(6):869-879. PubMed ID: 35262847
[TBL] [Abstract][Full Text] [Related]
2. Pooled Population Pharmacokinetic Analysis and Dose Recommendations for Ciprofloxacin in Intensive Care Unit Patients with Obesity.
van Rhee KP; Brüggemann RJM; Roberts JA; Sjövall F; van Hest RM; Elbers PWG; Abdulla A; van der Linden PD; Knibbe CAJ
J Clin Pharmacol; 2024 May; ():. PubMed ID: 38736038
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients.
Kees MG; Schaeftlein A; Haeberle HA; Kees F; Kloft C; Heininger A
J Antimicrob Chemother; 2013 Jun; 68(6):1331-7. PubMed ID: 23463212
[TBL] [Abstract][Full Text] [Related]
5. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
Fabre MA; Fuseau E; Ficheux H
J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of anidulafungin in ICU patients assessing inter- and intrasubject variability.
Kapralos I; Mainas E; Apostolopoulou O; Siopi M; Neroutsos E; Apostolidi S; Dimopoulos G; Sambatakou H; Valsami G; Meletiadis J; Dokoumetzidis A
Br J Clin Pharmacol; 2021 Mar; 87(3):1024-1032. PubMed ID: 32633039
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients.
Abdulla A; Rogouti O; Hunfeld NGM; Endeman H; Dijkstra A; van Gelder T; Muller AE; de Winter BCM; Koch BCP
Eur J Clin Pharmacol; 2020 Jul; 76(7):957-967. PubMed ID: 32307575
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations.
Conil JM; Georges B; Ruiz S; Rival T; Seguin T; Cougot P; Fourcade O; Pharmd GH; Saivin S
Br J Clin Pharmacol; 2011 Jan; 71(1):61-71. PubMed ID: 21143502
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Pharmacodynamics of Norvancomycin in Children With Malignant Hematological Disease.
Wang J; Li SC; Ye Q; Gao LL; Nie YM; Xu H; Wu M; Cao P; Wang Y
J Clin Pharmacol; 2020 Sep; 60(9):1220-1230. PubMed ID: 32488878
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
[TBL] [Abstract][Full Text] [Related]
13. Modeling and simulation approaches to evaluate pharmacokinetic sampling contamination from central venous catheters in pediatric pharmacokinetic studies of actinomycin-D: a report from the children's oncology group.
Edwards AY; Skolnik JM; Dombrowsky E; Patel D; Barrett JS
Cancer Chemother Pharmacol; 2012 Jul; 70(1):83-94. PubMed ID: 22623208
[TBL] [Abstract][Full Text] [Related]
14. Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients.
Roger C; Wallis SC; Louart B; Lefrant JY; Lipman J; Muller L; Roberts JA
J Antimicrob Chemother; 2016 Jun; 71(6):1643-50. PubMed ID: 26957490
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetic Analysis of Meropenem in Critically Ill Patients With Acute Kidney Injury Treated With Continuous Hemodiafiltration.
Niibe Y; Suzuki T; Yamazaki S; Suzuki T; Takahashi N; Hattori N; Nakada TA; Oda S; Ishii I
Ther Drug Monit; 2020 Aug; 42(4):588-594. PubMed ID: 32049890
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg.
Szałek E; Tomczak H; Kamińska A; Grabowski T; Smuszkiewicz P; Matysiak K; Wolc A; Kaczmarek Z; Grześkowiak E
Adv Med Sci; 2012; 57(2):217-23. PubMed ID: 22968336
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis.
Chen CY; Xie M; Gong J; Yu N; Wei R; Lei LL; Zhao SM; Li RM; Dong X; Zhang XL; Zhou Y; Li SL; Cui YM
Front Pharmacol; 2023; 14():1132367. PubMed ID: 37188268
[No Abstract] [Full Text] [Related]
18. Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function.
Gijsen M; Elkayal O; Annaert P; Van Daele R; Meersseman P; Debaveye Y; Wauters J; Dreesen E; Spriet I
Infect Drug Resist; 2022; 15():53-62. PubMed ID: 35035223
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic Modeling, Simulation, and Development of a Limited Sampling Strategy of Cycloserine in Patients with Multidrug-/Extensively Drug-Resistant Tuberculosis.
van der Galiën R; Boveneind-Vrubleuskaya NV; Peloquin C; Skrahina A; Touw DJ; Alffenaar JC
Clin Pharmacokinet; 2020 Jul; 59(7):899-910. PubMed ID: 31981103
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of ciprofloxacin in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study).
Cheng V; Abdul-Aziz MH; Burrows F; Buscher H; Corley A; Diehl A; Levkovich BJ; Pellegrino V; Reynolds C; Rudham S; Wallis SC; Welch SA; Roberts JA; Shekar K; Fraser JF;
Anaesth Crit Care Pain Med; 2022 Jun; 41(3):101080. PubMed ID: 35472580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
